Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-23
2010-11-09
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07829529
ABSTRACT:
The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
REFERENCES:
patent: 2005/0245449 (2005-07-01), Kongsbak et al.
patent: WO 93/06855 (1993-04-01), None
patent: WO 97/33995 (1997-09-01), None
patent: WO 98/58661 (1998-12-01), None
patent: WO 99/03498 (1999-01-01), None
patent: WO 99/66031 (1999-12-01), None
patent: WO 02/077218 (2002-10-01), None
patent: WO 02087605 (2002-11-01), None
patent: WO 03007983 (2003-01-01), None
patent: WO 03039581 (2003-05-01), None
patent: WO 03039582 (2003-05-01), None
patent: WO 03039584 (2003-05-01), None
patent: WO 03039590 (2003-05-01), None
U.S. Appl. No. 11/579,680, filed Nov. 7, 2006, Johannson et al.
Sato et al., “Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex,” Thrombosis Haemostasis, vol. 97, pp. 1138-1141 (1997).
Taniguchi et al., “Enhanced Expression of Urokinase Receptor Induced through the Tissue Factor VIIa Pathway in Huma Pancreatic Cancer”, (1998) Cancer Res., vol. 58, pp. 4461-4467.
Pendurthi et al., “Binding of Factor VIIa to Tissue Factor Induces Alterations in Gene Expression in Human Fibroblast Cells: Up-regulation of Poly(A) Polymerase,” (1997) Proc. Natl. Acad. Sci., vol. 94, pp. 12598-12603.
Camerer et al., “Coagulation Factors VIIa and Xa Induce Cell Signaling Leading to Up-regulation or the erg-1 Gene,” (1999) J Biol. Chem., vol. 274, No. 45, pp. 32225-32233.
Pendurthi et al., “Factor VIIa and Thrombin Induce the Expression of Cyr61 and Connective Tissue Growth Factor,” (2000) J. Biol. Chem., vol. 275, No. 19, pp. 14632-14641.
Ollivier, J.C. et al., “Vascular Endothelial Growth Factor Production by Fibroblasts in Response to Factor VIIa Binding to Tissue Factor Involves Thrombin and Factor Xa,” Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, vol. 20, pp. 1374-1381.
Ollivier et al., “Tissue Factor-Dependent Vascular Endothelial Growth Factor Production by Human Fibroblasts in Response to Activated Factor VII,” (1998) Blood, vol. 91, No. 8, pp. 2698-2703.
Niemi et al., “Haemostatis Disturbances in Burned Patients During Early Excision and Skin Grafting,” (1998) Blood Coag. Fibrinol., vol. 9, pp. 19-28.
Cunningham et al., “Tissue Factor and Factor VIIa Receptor/Ligand Interactions Induce Proinflammatory Effects in Macrophages,” (1999) Blood, vol. 94, No. 10, pp. 3413-3420.
Borgognone et al., “The Role of Antithrombin III and Factor VII in the Prognosis and Treatment of Burn Injury,” (1969) The Italian Journal of Plastic Surgery, vol. 21, pp. 459-464.
Dincer et al., “Human Recombinant Activated Factor Seven, Novoseven (rVIIa), in the Management of Massive Bleeding Despite Adequate Resuscitation in Major Trauma,” Disorders of Coagulation or Fibrinolysis, Abstract# 3918, p. 110b.
Ingerslev, J. et al., “Home Treatment with Recombinant Activated Factor VII: Results from One Centre,” (1998) Blood Coagulation or Fibronolysis, vol. 9 (Suppl 1), pp. S107-S110.
Petrini P. et al., “Treatment of Acute Bleeds with Recombinant Activated Factor VII During Immune Tolerance Therapy,” (1998) Blood Coagulation or Fibrinolysis, vol. 9 (Suppl 1), pp. S143-S146.
Aggarwal, A. et al., 43rdAnnual Meeting of the Society of Hematology, Part 2, Dec. 7-11, 2001.
Aggarwal, A. et al., Use of recombinant Activated Factor VII (rFV11a) in the Management of Intractable Bleeding in Surgical and Trauma Patients. Blood. vol. 98(11). p. 66B (2001).
Aitken, M.G., Recombinant factor VIIa, Emergency Medicine Australasia, vol. 16, pp. 446-455 (2004).
Alcorn, K. et al., Single Institution Experience of Recombinant Activated Factor VII (Novo-Seven) in the Management of Intractable Bleeding in Surgical and Trauma Patients, Blood, vol. 100(11), p. 3840 (2002).
Aldouri, M., The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients, Pathophysiology of Haemostasis and Thrombosis, vol. 32(Supp11), pp. 141-146 (2002).
Argall, J., Factor VIIa for intractable blood loss in trauma, Emergency Medical Journal, vol. 19. pp. 556-557 (Nov. 2002).
Armand, R. et al., Treating Coagulopathy in Trauma Patients, Transfusion Medicine Reviews, vol. 17(3). pp. 223-231 (2003).
Arvieux, C. et al., Damage control laparotomy for haemorragic abdominal trauma, Annales De Chiruaie. vol. 128, pp. 150-158 (2003).
Becton, D. et al., Treatment of Bleeding with rFVIIa (NovoSeven®) in Four Diverse Cases, Blood, vol. 98(11), pp. 263a (2001).
Bianchi et al. Thromb Haemost., vol. 91(1), pp. 203-204 (2004).
Borgognone et al., Riv Ital Di Chi Plastica, Vol. 21(4), pp. 459-64 (1989).
Chiu, J. et al., Transfusion-sparing hemostatic agents, Transfusion Medicine, vol. 9, pp. 544-550 (2002).
Dejgaard, A., Update on Novo Nordisk's clinical trial programme on NovoSeven®, Blood Coagulation and Fibrinolysis. vol. 14(suppl), pp. 39-41 (2003).
Dutton, R. et al., Recombinant Factor VIIa for Controlling of Hemorrhage: Early Experience in Critically III Trauma Patients, Journal of Clinical Anesthesia, vol. 15, pp. 184-188 (2003).
Eikelboom, J. et al., Recombinant Activated Factor VIIa for Massive Hemorrhage in Non-Hemophiliac Patients: The Australian Experience, Blood, vol. 100(11), p. 2800 (2002).
Eikelboom, J.W. et al., Recombinant activated factor VII for the treatment of life-threatening haemorrhage, Blood Coagulation and Fibrinolysis, vol. 14, pp. 713-717 (2003).
Erhardtsen, E., Ongoing NovoSeven® Trials, Intensive Care Medicine, vol. 28, pp. 248-55 (2002).
Erhardtsen, E., To General Haemostasis-the Evidence-Based Route, Pathophysiology of Haemostasis and Thrombosis, vol. 32(suppll), pp. 47-52 (200).
Essex, D. et al., 42ndAnnual Meeting of the American Society of Hematology, Dec. 1-5, 2000.
Essex, D. et al., Successful Use of Recombinant Factor VIIa for Trauma-Associated Massive Hemorrhage, Blood, vol. 96(11Pat), p. 268A (2000).
Grounds, Mike, Recombinant factor VIIa and its use in severe bleeding in surgery and trauma: a review, Blood Reviews, vol. 17, pp. S11-S21 (2003).
Hardy, J-F., Managing uncontrolled hemorrhage in trauma and surgery: a novel and promising approach, Canadian Journal of Anesthesia, vol. 49(suppl), pp. 84-86 (2002).
Hedner, U., General Haemostatic Agents- Fact or Fiction?, Pathophysiology of Haemostasis and Thrombosis, vol. 32(suppl 1), pp. 33-36 (2002).
Holcomb, J., Discussion, The Journal of Trauma, vol. 51(3), pp. 438-439 (2001).
Holcomb, J.B. et al., Use of Recombinant FAIIa for Intraperitoneal Coagulopathic Bleeding in a Septic Patient, Current Surgery, vol. 60(4), pp. 423-427 (2003).
Horton, J.W., Toxicology, vol. 189, pp. 75-88 (2003).
Jeroukhimov, I. et al., Early Injection of High-Dose Recombinant Factor VIIa Decreases Blood Loss and Prolongs Time from Injury to Death in Experimental Liver Injury, The Journal of Trauma, vol. 53(6), pp. 1053-1057 (2002).
Kampruisen, P.W. et al., Control of Life-Threatening Pulmonary Bleeding with Activated Recombinant Factor VII, The American Journal of Medicine, vol. 112, pp. 332-333 (2002).
Kenet, G. et al., Treatment of traumatic bleeding with recombinant factor VIIa, The Lancet, vol. 354, p. 1879 (1999).
Kristensen, A.T. et al., Potential uses of recombinant human factor VIIA in veterinary medicine, The Veterinary Clinics of North America Small Animal Practice, vol. 33, pp. 1437-1451 (2003).
Kulkarni, R. et al., Recombinant factor VIIa use in paediatric traumatic liver injuries in children, JVF Congress of WHF Seville, abstract, (2002).
Lynn, M. et al., Early Use of Recombinant Factor VIIa Improves Mean Arterial Pressure and May Potentially Decrease Mortality in Experimental Hemorrhagic Shock: A Pilot Study, The Journal of Trauma, vol. 52, pp. 703-707 (2002).
Lynn, M. et al., Updates in the management of se
Ezban Mirella
Petersen Lars Christian
Siegbahn Agneta
Carlson Karen Cochrane
Chen Teresa
Green Reza
Novo Nordisk Health Care A/G
LandOfFree
Use of factor VIIa or a tissue factor antagonist for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of factor VIIa or a tissue factor antagonist for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of factor VIIa or a tissue factor antagonist for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203190